Tianjin TEDA Biomedical Engineering（8189）株式概要天津泰達生物医学工程有限公司は、その子会社とともに、中華人民共和国において生物学的複合肥料製品の研究、開発、製造、販売に従事している。 詳細8189 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6リスク分析キャッシュランウェイが1年未満である 意味のある時価総額がありません ( HK$282M )Hong Kong市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る8189 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW483,572 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA483,572 investors already sharing narrativesYour Fair ValueHK$Current PriceHK$0.1461.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-178m523m2016201920222025202620282031Revenue CN¥519.6mEarnings CN¥48.2mAdvancedSet Fair ValueView all narrativesTianjin TEDA Biomedical Engineering Company Limited 競合他社Ko Yo Chemical (Group)Symbol: SEHK:827Market cap: HK$295.2mDongguang ChemicalSymbol: SEHK:1702Market cap: HK$894.2mSinofert HoldingsSymbol: SEHK:297Market cap: HK$8.8bMigao Group HoldingsSymbol: SEHK:9879Market cap: HK$8.5b価格と性能株価の高値、安値、推移の概要Tianjin TEDA Biomedical Engineering過去の株価現在の株価HK$0.1452週高値HK$0.4852週安値HK$0.11ベータ-0.441ヶ月の変化-5.33%3ヶ月変化-29.35%1年変化-70.11%3年間の変化100.00%5年間の変化-32.38%IPOからの変化-76.33%最新ニュースNew Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (HK$260.3m market cap, or US$33.2m).お知らせ • May 02Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026, at 10:00 China Standard Time. Location: 9th floor, block a2, tianda high-tech park, no. 80, the 4th avenue, teda, tianjin, ChinaReported Earnings • Apr 04Full year 2025 earnings releasedFull year 2025 results: Revenue: CN¥523.0m (up 36% from FY 2024). Net loss: CN¥90.8m (loss widened 206% from FY 2024).New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (HK$640.2m market cap, or US$81.7m).お知らせ • Mar 13Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2025 Results on Mar 31, 2026Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Dec 31Tianjin TEDA Biomedical Engineering Company Limited Announces Directorate AppointmentsTianjin TEDA Biomedical Engineering Company Limited, at the EGM held on 31 December 2025 approved election of Mr. Yang Zeng and Mr. Xia Alan Zhe as an executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Wang Lei as a non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Chen Jiang as an independent non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company.最新情報をもっと見るRecent updatesNew Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (HK$260.3m market cap, or US$33.2m).お知らせ • May 02Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026, at 10:00 China Standard Time. Location: 9th floor, block a2, tianda high-tech park, no. 80, the 4th avenue, teda, tianjin, ChinaReported Earnings • Apr 04Full year 2025 earnings releasedFull year 2025 results: Revenue: CN¥523.0m (up 36% from FY 2024). Net loss: CN¥90.8m (loss widened 206% from FY 2024).New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (HK$640.2m market cap, or US$81.7m).お知らせ • Mar 13Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2025 Results on Mar 31, 2026Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Dec 31Tianjin TEDA Biomedical Engineering Company Limited Announces Directorate AppointmentsTianjin TEDA Biomedical Engineering Company Limited, at the EGM held on 31 December 2025 approved election of Mr. Yang Zeng and Mr. Xia Alan Zhe as an executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Wang Lei as a non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Chen Jiang as an independent non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company.分析記事 • Dec 04Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Shares May Have Run Too Fast Too SoonWhen close to half the companies in the Chemicals industry in Hong Kong have price-to-sales ratios (or "P/S") below...New Risk • Nov 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: HK$768.2m (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risk Market cap is less than US$100m (HK$768.2m market cap, or US$98.8m).Reported Earnings • Aug 31First half 2025 earnings releasedFirst half 2025 results: Revenue: CN¥226.4m (up 7.0% from 1H 2024). Net loss: CN¥6.43m (loss widened 56% from 1H 2024).お知らせ • Aug 15Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2025 Results on Aug 29, 2025Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • May 08+ 1 more updateTianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 24, 2025Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 24, 2025, at 10:00 China Standard Time. Location: 9th floor, block a2, tianda high-tech park, no. 80, the 4th avenue, teda, tianjin, Chinaお知らせ • Apr 09Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 38.8125 million.Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 38.8125 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 103,500,000 Price\Range: HKD 0.375 Transaction Features: Subsequent Direct Listing分析記事 • Apr 07Some Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shareholders Look For Exit As Shares Take 29% PoundingThe Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) share price has softened a substantial 29% over...Reported Earnings • Apr 02Full year 2024 earnings released: CN¥0.016 loss per share (vs CN¥0.008 loss in FY 2023)Full year 2024 results: CN¥0.016 loss per share (further deteriorated from CN¥0.008 loss in FY 2023). Revenue: CN¥385.5m (down 3.1% from FY 2023). Net loss: CN¥29.6m (loss widened 104% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year whereas the company’s share price has increased by 43% per year.お知らせ • Apr 01Tianjin TEDA Biomedical Engineering Company Limited Announces Re-Designation of He Xin from Executive Director to Non-Executive Director, Effect from 31 March 2025The board of directors of Tianjin TEDA Biomedical Engineering Company Limited announced that Mr. He Xin ("Mr. He") was re-designated from executive Director to non-executive Director of the Company with effect from 31 March 2025 as he would like to devote more time to his personal developments. Mr. He, aged 55, postgraduate, graduated from Beijing Jiaotong University majoring in Mechanical Engineering. From July 1992 to June 1994, he served as a business manager of the export department of China Railway Import and Export Company under the Ministry of Railway From June 1994 to May 2005, he worked as a secretary of the administrative department of Shenzhen Golden Century Development Company Limited From May 2005 to September 2009, he served as an investment manager of the international department of China Merchants Securities Company Limited. From September 2010 to March 2014, he held a position as a vice president of Beijing Yingguxinye Investment Co. Ltd. From March 2014 to August 2016, he held positions as a director and a general manager of Ningxia Yinggu Industry Company Limited. From August 2016 to present, he has been serving as a general manager of Beijing Yingguxinye Investment Co. Ltd. Mr. He joined the Company in December 2018 and was appointed as executive director of the Company.New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).お知らせ • Mar 12Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2024 results on Mar 31, 2025お知らせ • Feb 20Tianjin TEDA Biomedical Engineering Company Limited has completed a Follow-on Equity Offering in the amount of HKD 50.9625 million.Tianjin TEDA Biomedical Engineering Company Limited has completed a Follow-on Equity Offering in the amount of HKD 50.9625 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 135,900,000 Price\Range: HKD 0.375 Transaction Features: Subsequent Direct Listing分析記事 • Jan 17Subdued Growth No Barrier To Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) With Shares Advancing 55%Despite an already strong run, Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shares have been...お知らせ • Jan 17Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 63.441 million.Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 63.441 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 239,400,000 Price\Range: HKD 0.265 Transaction Features: Subsequent Direct Listing分析記事 • Dec 02Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Stock Rockets 38% As Investors Are Less Pessimistic Than ExpectedTianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shareholders would be excited to see that the share...分析記事 • Oct 17There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 73% Price JumpDespite an already strong run, Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shares have been...お知らせ • Oct 17Tianjin TEDA Biomedical Engineering Company Limited Announces Supervisory Committee ChangesTianjin TEDA Biomedical Engineering Company Limited announced that Ms. Yang Chunyan has submitted her resignation to the Supervisory Committee due to her resignation from Tianjin TEDA Biomedical Engineering Company Limited (the "Company"). She has resigned as the Supervisor and Chairman of the Supervisory Committee, and her resignation will take effect on October 14, 2024. Ms. Yang has confirmed that she has no disagreement with the Board, and there is no other matter in respect of her resignation that needs to be brought to the attention of the shareholders of the Company. The resignation of the Resigning Supervisor will not result in the total number of the Supervisors falling below the statutory requirements under the relevant PRC laws and regulations and will not affect the operation of the Supervisory Committee. The Company will complete the election of Supervisor as soon as practicable in accordance with the Articles of Association and other relevant regulations. According to the requirements of the Articles, at the eighth meeting of the eighth session of the Supervisory Committee held on 15 October 2024, Ms. Liu Jinyu was elected as the Chairman of the eight session of the Supervisory Committee for a term to the date of expiry of the term of the eighth session of the Supervisory Committee.Reported Earnings • Aug 31First half 2024 earnings released: CN¥0.002 loss per share (vs CN¥0.006 loss in 1H 2023)First half 2024 results: CN¥0.002 loss per share (improved from CN¥0.006 loss in 1H 2023). Revenue: CN¥211.6m (up 14% from 1H 2023). Net loss: CN¥4.12m (loss narrowed 63% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.分析記事 • Aug 16There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 38% Price JumpThe Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) share price has done very well over the last...お知らせ • Aug 15Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2024 Results on Aug 30, 2024Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2024 results on Aug 30, 2024お知らせ • Jun 08Tianjin Teda Biomedical Engineering Company Limited Appoints Mr. Tu Xiangzhen as the Independent Non-Executive DirectorTianjin TEDA Biomedical Engineering Company Limited announced that at its AGM held on 7 June 2024, the shareholders approved the appointment of Mr. Tu Xiangzhen as the independent non-executive Director of the Company.分析記事 • May 07Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some RiskTianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shareholders that were waiting for something to happen...お知らせ • Apr 21Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 07, 2024Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 07, 2024, at 10:00 China Standard Time. Location: 9th Floor, Block A2, Tianda High-Tech Park, No. 80, The 4th Avenue, TEDA, Tainjin China Agenda: To consider and, if thought fit, approve the audited consolidated accounts of the Group for the year ended 31 December 2023; To consider and, if thought fit, approve the report of the directors of the Company; To consider and, if thought fit, approve the report of the Supervisory Committee of the Company; to consider and, if thought fit, approve the proposal of appointing Fan, Chan & Co. Limited as auditor of the Company for the financial year of 2024 and authorize the Directors of the Company to fix their remuneration; and to consider and, if thought fit, approve the appointment of Mr. Tu Xiangzhen as the independent non-executive Director of the Company; and to consider other matters.Reported Earnings • Mar 30Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.015 loss in FY 2022)Full year 2023 results: CN¥0.008 loss per share (improved from CN¥0.015 loss in FY 2022). Revenue: CN¥398.0m (down 12% from FY 2022). Net loss: CN¥14.6m (loss narrowed 48% from FY 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Mar 28+ 1 more updateTianjin TEDA Biomedical Engineering Company Limited Announces Resignation of Mr. Li Xudong as Independent Non-Executive Director and Chairman of the Audit CommitteeTianjin TEDA Biomedical Engineering Company Limited announced that the Board has accepted the resignation of Mr. Li Xudong as independent non-executive Director with effect from 28 March 2024. Mr. Li will also cease to be the chairman of the Audit Committee of the company with effect from 28 March 2024.お知らせ • Mar 26Tianjin TEDA Biomedical Engineering Company Limited Announces Chief Executive Officer ChangesTianjin TEDA Biomedical Engineering Company Limited announced that Mr. Qin Wenhua resigned as the Joint CEO due to his busy schedule and his other business engagements with effect from 26 March 2024. Before Mr. Qin resigned as the Joint CEO, he and Ms. Sun Li jointly served as the Joint CEO. After Mr. Qin resigned as the joint CEO, Ms. Sun became the CEO of the Company. As Ms. Sun now serves as both the Chairman and the CEO, such practice deviates from code provision A.2.1 of the Code of Corporate Governance. The Board is of the opinion that it is appropriate and in the best interests of the Company for Ms. Sun to hold both positions as it helps to maintain the continuity of the policies and the stability of the operations of the Company.お知らせ • Mar 13Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2023 Final Results on Mar 28, 2024Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2023 final results on Mar 28, 2024Reported Earnings • Nov 11Third quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 3Q 2022)Third quarter 2023 results: CN¥0.003 loss per share (improved from CN¥0.004 loss in 3Q 2022). Revenue: CN¥119.3m (up 20% from 3Q 2022). Net loss: CN¥6.04m (loss narrowed 28% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Oct 25Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2023 Results on Nov 09, 2023Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q3, 2023 results on Nov 09, 2023分析記事 • Sep 12Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Aug 11Second quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 2Q 2022)Second quarter 2023 results: CN¥0.003 loss per share (improved from CN¥0.004 loss in 2Q 2022). Revenue: CN¥99.5m (down 14% from 2Q 2022). Net loss: CN¥5.37m (loss narrowed 25% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Jul 25Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2023 Results on Aug 10, 2023Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2023 results on Aug 10, 2023分析記事 • Apr 17Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% HidingUnfortunately for some shareholders, the Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) share price...分析記事 • Apr 07Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Apr 01Full year 2022 earnings released: CN¥0.015 loss per share (vs CN¥0.022 loss in FY 2021)Full year 2022 results: CN¥0.015 loss per share (improved from CN¥0.022 loss in FY 2021). Revenue: CN¥449.7m (down 5.6% from FY 2021). Net loss: CN¥28.1m (loss narrowed 34% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yongkang Wang was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 15Tianjin TEDA Biomedical Engineering Company Limited Announces Mr. Hao Zhihui Will Retire as an Executive DirectorTianjin TEDA Biomedical Engineering Company Limited announced Mr. Hao Zhihui will retire as an executive director at the EGM with effect from the conclusion of the EGM due to his retirement and will not offer himself for re-election. The number of members of the Board does not meet the requirements of the Company's Articles of Association as it has not yet identified a suitable candidate to succeed as an executive director. The Board will identify a suitable candidate to serve as an executive director as soon as practicable in order to comply with the requirements of the Company's Articles of Association.Reported Earnings • Nov 13Third quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥0.001 profit in 3Q 2021)Third quarter 2022 results: CN¥0.44 loss per share (down from CN¥0.001 profit in 3Q 2021). Revenue: CN¥99.8m (down 14% from 3Q 2021). Net loss: CN¥8.38m (down CN¥9.39m from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.分析記事 • Nov 01Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Oct 26Tianjin TEDA Biomedical Engineering Company Limited to Report Nine Months, 2022 Results on Nov 10, 2022Tianjin TEDA Biomedical Engineering Company Limited announced that they will report nine months, 2022 results on Nov 10, 2022お知らせ • Sep 07Tianjin Teda Biomedical Engineering Company Limited Announces Executive ChangesTianjin TEDA Biomedical Engineering Company Limited (the Company) hereby announced that Mr. Qin Wenhua has been appointed as the Joint Chief Executive Officer of the Company and Ms. Sun Li has been re-designated as the Joint Chief Executive Officer of the Company from the Chief Executive Officer of the Company with effect from 6 September 2022. MR. QIN WENHUA Mr. Qin Wenhua (Mr. Qin), aged 56, graduated from Sun Yat-sen University in 1988 with a bachelor's degree in theoretical physics. Mr. Qin has 28 years of experience in business start-up. He has successively led and founded various fast-moving consumer goods companies such as Yunnan Red, Yunnan Shangri La Wine Industry, and Impression Wine Industry, all of which have developed into well-known brands in the industry. Mr. Qin has strategic framework capabilities in product design and positioning, brand marketing, consumer demand mining and service construction. Qin has successively established Jiangsu Weidi Electronic Trading Center Co. Ltd. Shanghai Yunyang Biotechnology Co. Ltd. Shanghai Meika Coffee Co. Ltd., Wisdom Cloud Drink Co. Ltd. Shanghai Weidi Network Technology Co. Ltd. other companies, and has experience in the implementation of and multiple consumer goods DTC projects. Ms. Sun Li (Ms. Sun), aged 49, holds a doctorate degree in Business Administration from the City University of Hong Kong and graduated from Central South University with a bachelor's degree in Technological Economics and with a master 's degree in Administration, respectively. Ms. Sun has engaged in investment banking for 15 years, and was among the first batch of sponsor representatives from the Securities Association of China in 2004. She is a member of Alxa SEE Conservation, an environmental protection charity organization for Chinese entrepreneurs. From May 2013 until now, Sun served as president, director and co-partner of Beijing Yingguxinye Investment Co. Ltd. In September 2014, she was the founding member of Tianjin Teda Wings of the Angel. Investor Club. From May 2015 until now, Sun was appointed as supervisors of Shenzhen Xiangyong Investment Company Limited and Dongguan Lvye Fertilisers Company Limited. From September 2015 until now, Sun, as the beneficial owner of Beijing Tianyuhongtai Technology Co. Ltd. held its 16% shares. From December 2015 until now, she was appointed as a director of Beijing Yingguchuangrong Information Technology Co. Ltd. From August 2015 until now, Ms. Sun was appointed as an executive director and the Chairman. of the Board of the Company. From September 2015 to January 2019 and from 30 December 2019, Ms. Sun concurrently serves Officer of the Company.Reported Earnings • Aug 10Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CN¥116.0m (down 1.2% from 2Q 2021). Net loss: CN¥7.20m (down CN¥8.18m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 23Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2022 Results on Aug 09, 2022Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2022 results on Aug 09, 2022お知らせ • Jul 19Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) entered into the Equity Transfer Agreement to acquire Shanghai Weidi Network Technology Company from three shareholders for CNY12.8 million.Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) entered into the Equity Transfer Agreement to acquire Shanghai Weidi Network Technology Company from three shareholders for CNY12.8 million on July 18, 2022. The net asset value of Shanghai Weidi as of 30 June 2022 was RMB13.1 million.Reported Earnings • May 11First quarter 2022 earnings released: CN¥0.003 loss per share (vs CN¥0 in 1Q 2021)First quarter 2022 results: CN¥0.003 loss per share (down from CN¥0 in 1Q 2021). Revenue: CN¥89.2m (down 28% from 1Q 2021). Net loss: CN¥6.04m (loss widened CN¥5.88m from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yongkang Wang was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 23Tianjin TEDA Biomedical Engineering Company Limited to Report Q1, 2022 Results on May 10, 2022Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q1, 2022 results on May 10, 2022分析記事 • Apr 21Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Apr 03Full year 2021 earnings releasedFull year 2021 results: Revenue: CN¥476.4m (up 29% from FY 2020). Net loss: CN¥42.3m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Feb 09Tianjin TEDA Biomedical Engineering Company Limited Approves Appointment of Mr. Zhao Zhiyou as the Independent SupervisorTianjin TEDA Biomedical Engineering Company Limited announced that at its special general meeting held on February 8, 2022, shareholders approved the appointment of Mr. Zhao Zhiyou as the independent supervisor of the company for a term commencing from the date of passing this resolution and ending upon the conclusion of the seventh session of the Supervisory Committee.Reported Earnings • Nov 11Third quarter 2021 earnings released: EPS CN¥0.001 (vs CN¥0.006 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥115.4m (up 34% from 3Q 2020). Net income: CN¥1.01m (up CN¥11.7m from 3Q 2020). Profit margin: 0.9% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.分析記事 • Oct 26Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Aug 10Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥117.4m (up 21% from 2Q 2020). Net income: CN¥975.2k (up 200% from 2Q 2020). Profit margin: 0.8% (up from 0.3% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.分析記事 • Apr 06Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Executive Departure • Apr 02Non-Executive Director has left the companyOn the 26th of March, Li Gai's tenure as Non-Executive Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Li's name. Li is the only executive to leave the company over the last 12 months.Reported Earnings • Mar 28Full year 2020 earnings released: CN¥0.025 loss per share (vs CN¥0.045 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CN¥369.4m (up 3.0% from FY 2019). Net loss: CN¥48.0m (loss narrowed 43% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 09Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2020 results on Mar 24, 2021分析記事 • Dec 22Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Oct 28Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2020 Results on Nov 10, 2020Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q3, 2020 results on Nov 10, 2020お知らせ • Jul 25Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2020 Results on Aug 10, 2020Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2020 results on Aug 10, 2020株主還元8189HK ChemicalsHK 市場7D-2.7%4.7%-0.08%1Y-70.1%1.5%-1.5%株主還元を見る業界別リターン: 8189過去 1 年間で1.5 % の収益を上げたHong Kong Chemicals業界を下回りました。リターン対市場: 8189は、過去 1 年間で-1.5 % のリターンを上げたHong Kong市場を下回りました。価格変動Is 8189's price volatile compared to industry and market?8189 volatility8189 Average Weekly Movement14.7%Chemicals Industry Average Movement6.7%Market Average Movement7.8%10% most volatile stocks in HK Market15.9%10% least volatile stocks in HK Market3.7%安定した株価: 8189の株価は、 Hong Kong市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 8189の 週次ボラティリティ は、過去 1 年間で9%から15%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2000273Li Sunbioteda.com天津泰達生物医学工程有限公司は、その子会社とともに、中華人民共和国において生物学的配合肥料製品の研究、開発、製造、販売に従事している。同社は、生物学的複合肥料製品と高齢者ケア・ヘルスケアサービスの2つのセグメントで事業を展開している。同社の生物学的複合肥料製品には、穀物、果物、野菜のバランスの取れた成長を促進するために使用される、窒素、リン、カリウムを様々な配合で混合した活性肥料が含まれる。同社はまた、総合的な高齢者ケアとヘルスケア、高齢者設備リースサービス、高齢者ケアのコンサルティング、助言、管理、評価サービスの提供にも携わっている。さらに、脳波写真（EEG）診断検出サービスの提供およびライセンス供与、EEG検出および診断技術サービスも行っている。さらに、生物医学科学技術プロジェクトの研究、開発、製造、応用、地域土壌資源の調整と修復研究サービス、ワインの取引、システムプラットフォーム開発専門、土壌環境品質基準研究サービスの提供、情報伝送、ソフトウェア、情報技術サービス業にも従事している。天津泰達生物医学工程有限公司は2000年に設立され、中華人民共和国天津市に本社を置く。もっと見るTianjin TEDA Biomedical Engineering Company Limited 基礎のまとめTianjin TEDA Biomedical Engineering の収益と売上を時価総額と比較するとどうか。8189 基礎統計学時価総額HK$281.67m収益（TTM）-HK$105.64m売上高(TTM)HK$608.28m0.5xP/Sレシオ-2.9xPER（株価収益率8189 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計8189 損益計算書（TTM）収益CN¥522.97m売上原価CN¥552.36m売上総利益-CN¥29.40mその他の費用CN¥61.42m収益-CN¥90.82m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.043グロス・マージン-5.62%純利益率-17.37%有利子負債／自己資本比率3,591.4%8189 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/11 13:52終値2026/08/11 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tianjin TEDA Biomedical Engineering Company Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (HK$260.3m market cap, or US$33.2m).
お知らせ • May 02Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026, at 10:00 China Standard Time. Location: 9th floor, block a2, tianda high-tech park, no. 80, the 4th avenue, teda, tianjin, China
Reported Earnings • Apr 04Full year 2025 earnings releasedFull year 2025 results: Revenue: CN¥523.0m (up 36% from FY 2024). Net loss: CN¥90.8m (loss widened 206% from FY 2024).
New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (HK$640.2m market cap, or US$81.7m).
お知らせ • Mar 13Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2025 Results on Mar 31, 2026Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Dec 31Tianjin TEDA Biomedical Engineering Company Limited Announces Directorate AppointmentsTianjin TEDA Biomedical Engineering Company Limited, at the EGM held on 31 December 2025 approved election of Mr. Yang Zeng and Mr. Xia Alan Zhe as an executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Wang Lei as a non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Chen Jiang as an independent non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company.
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (HK$260.3m market cap, or US$33.2m).
お知らせ • May 02Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026, at 10:00 China Standard Time. Location: 9th floor, block a2, tianda high-tech park, no. 80, the 4th avenue, teda, tianjin, China
Reported Earnings • Apr 04Full year 2025 earnings releasedFull year 2025 results: Revenue: CN¥523.0m (up 36% from FY 2024). Net loss: CN¥90.8m (loss widened 206% from FY 2024).
New Risk • Mar 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (HK$640.2m market cap, or US$81.7m).
お知らせ • Mar 13Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2025 Results on Mar 31, 2026Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Dec 31Tianjin TEDA Biomedical Engineering Company Limited Announces Directorate AppointmentsTianjin TEDA Biomedical Engineering Company Limited, at the EGM held on 31 December 2025 approved election of Mr. Yang Zeng and Mr. Xia Alan Zhe as an executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Wang Lei as a non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Chen Jiang as an independent non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company.
分析記事 • Dec 04Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Shares May Have Run Too Fast Too SoonWhen close to half the companies in the Chemicals industry in Hong Kong have price-to-sales ratios (or "P/S") below...
New Risk • Nov 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: HK$768.2m (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risk Market cap is less than US$100m (HK$768.2m market cap, or US$98.8m).
Reported Earnings • Aug 31First half 2025 earnings releasedFirst half 2025 results: Revenue: CN¥226.4m (up 7.0% from 1H 2024). Net loss: CN¥6.43m (loss widened 56% from 1H 2024).
お知らせ • Aug 15Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2025 Results on Aug 29, 2025Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • May 08+ 1 more updateTianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 24, 2025Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 24, 2025, at 10:00 China Standard Time. Location: 9th floor, block a2, tianda high-tech park, no. 80, the 4th avenue, teda, tianjin, China
お知らせ • Apr 09Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 38.8125 million.Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 38.8125 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 103,500,000 Price\Range: HKD 0.375 Transaction Features: Subsequent Direct Listing
分析記事 • Apr 07Some Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shareholders Look For Exit As Shares Take 29% PoundingThe Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) share price has softened a substantial 29% over...
Reported Earnings • Apr 02Full year 2024 earnings released: CN¥0.016 loss per share (vs CN¥0.008 loss in FY 2023)Full year 2024 results: CN¥0.016 loss per share (further deteriorated from CN¥0.008 loss in FY 2023). Revenue: CN¥385.5m (down 3.1% from FY 2023). Net loss: CN¥29.6m (loss widened 104% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year whereas the company’s share price has increased by 43% per year.
お知らせ • Apr 01Tianjin TEDA Biomedical Engineering Company Limited Announces Re-Designation of He Xin from Executive Director to Non-Executive Director, Effect from 31 March 2025The board of directors of Tianjin TEDA Biomedical Engineering Company Limited announced that Mr. He Xin ("Mr. He") was re-designated from executive Director to non-executive Director of the Company with effect from 31 March 2025 as he would like to devote more time to his personal developments. Mr. He, aged 55, postgraduate, graduated from Beijing Jiaotong University majoring in Mechanical Engineering. From July 1992 to June 1994, he served as a business manager of the export department of China Railway Import and Export Company under the Ministry of Railway From June 1994 to May 2005, he worked as a secretary of the administrative department of Shenzhen Golden Century Development Company Limited From May 2005 to September 2009, he served as an investment manager of the international department of China Merchants Securities Company Limited. From September 2010 to March 2014, he held a position as a vice president of Beijing Yingguxinye Investment Co. Ltd. From March 2014 to August 2016, he held positions as a director and a general manager of Ningxia Yinggu Industry Company Limited. From August 2016 to present, he has been serving as a general manager of Beijing Yingguxinye Investment Co. Ltd. Mr. He joined the Company in December 2018 and was appointed as executive director of the Company.
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
お知らせ • Mar 12Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2024 results on Mar 31, 2025
お知らせ • Feb 20Tianjin TEDA Biomedical Engineering Company Limited has completed a Follow-on Equity Offering in the amount of HKD 50.9625 million.Tianjin TEDA Biomedical Engineering Company Limited has completed a Follow-on Equity Offering in the amount of HKD 50.9625 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 135,900,000 Price\Range: HKD 0.375 Transaction Features: Subsequent Direct Listing
分析記事 • Jan 17Subdued Growth No Barrier To Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) With Shares Advancing 55%Despite an already strong run, Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shares have been...
お知らせ • Jan 17Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 63.441 million.Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 63.441 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 239,400,000 Price\Range: HKD 0.265 Transaction Features: Subsequent Direct Listing
分析記事 • Dec 02Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Stock Rockets 38% As Investors Are Less Pessimistic Than ExpectedTianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shareholders would be excited to see that the share...
分析記事 • Oct 17There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 73% Price JumpDespite an already strong run, Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shares have been...
お知らせ • Oct 17Tianjin TEDA Biomedical Engineering Company Limited Announces Supervisory Committee ChangesTianjin TEDA Biomedical Engineering Company Limited announced that Ms. Yang Chunyan has submitted her resignation to the Supervisory Committee due to her resignation from Tianjin TEDA Biomedical Engineering Company Limited (the "Company"). She has resigned as the Supervisor and Chairman of the Supervisory Committee, and her resignation will take effect on October 14, 2024. Ms. Yang has confirmed that she has no disagreement with the Board, and there is no other matter in respect of her resignation that needs to be brought to the attention of the shareholders of the Company. The resignation of the Resigning Supervisor will not result in the total number of the Supervisors falling below the statutory requirements under the relevant PRC laws and regulations and will not affect the operation of the Supervisory Committee. The Company will complete the election of Supervisor as soon as practicable in accordance with the Articles of Association and other relevant regulations. According to the requirements of the Articles, at the eighth meeting of the eighth session of the Supervisory Committee held on 15 October 2024, Ms. Liu Jinyu was elected as the Chairman of the eight session of the Supervisory Committee for a term to the date of expiry of the term of the eighth session of the Supervisory Committee.
Reported Earnings • Aug 31First half 2024 earnings released: CN¥0.002 loss per share (vs CN¥0.006 loss in 1H 2023)First half 2024 results: CN¥0.002 loss per share (improved from CN¥0.006 loss in 1H 2023). Revenue: CN¥211.6m (up 14% from 1H 2023). Net loss: CN¥4.12m (loss narrowed 63% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
分析記事 • Aug 16There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 38% Price JumpThe Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) share price has done very well over the last...
お知らせ • Aug 15Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2024 Results on Aug 30, 2024Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2024 results on Aug 30, 2024
お知らせ • Jun 08Tianjin Teda Biomedical Engineering Company Limited Appoints Mr. Tu Xiangzhen as the Independent Non-Executive DirectorTianjin TEDA Biomedical Engineering Company Limited announced that at its AGM held on 7 June 2024, the shareholders approved the appointment of Mr. Tu Xiangzhen as the independent non-executive Director of the Company.
分析記事 • May 07Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some RiskTianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) shareholders that were waiting for something to happen...
お知らせ • Apr 21Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 07, 2024Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 07, 2024, at 10:00 China Standard Time. Location: 9th Floor, Block A2, Tianda High-Tech Park, No. 80, The 4th Avenue, TEDA, Tainjin China Agenda: To consider and, if thought fit, approve the audited consolidated accounts of the Group for the year ended 31 December 2023; To consider and, if thought fit, approve the report of the directors of the Company; To consider and, if thought fit, approve the report of the Supervisory Committee of the Company; to consider and, if thought fit, approve the proposal of appointing Fan, Chan & Co. Limited as auditor of the Company for the financial year of 2024 and authorize the Directors of the Company to fix their remuneration; and to consider and, if thought fit, approve the appointment of Mr. Tu Xiangzhen as the independent non-executive Director of the Company; and to consider other matters.
Reported Earnings • Mar 30Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.015 loss in FY 2022)Full year 2023 results: CN¥0.008 loss per share (improved from CN¥0.015 loss in FY 2022). Revenue: CN¥398.0m (down 12% from FY 2022). Net loss: CN¥14.6m (loss narrowed 48% from FY 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Mar 28+ 1 more updateTianjin TEDA Biomedical Engineering Company Limited Announces Resignation of Mr. Li Xudong as Independent Non-Executive Director and Chairman of the Audit CommitteeTianjin TEDA Biomedical Engineering Company Limited announced that the Board has accepted the resignation of Mr. Li Xudong as independent non-executive Director with effect from 28 March 2024. Mr. Li will also cease to be the chairman of the Audit Committee of the company with effect from 28 March 2024.
お知らせ • Mar 26Tianjin TEDA Biomedical Engineering Company Limited Announces Chief Executive Officer ChangesTianjin TEDA Biomedical Engineering Company Limited announced that Mr. Qin Wenhua resigned as the Joint CEO due to his busy schedule and his other business engagements with effect from 26 March 2024. Before Mr. Qin resigned as the Joint CEO, he and Ms. Sun Li jointly served as the Joint CEO. After Mr. Qin resigned as the joint CEO, Ms. Sun became the CEO of the Company. As Ms. Sun now serves as both the Chairman and the CEO, such practice deviates from code provision A.2.1 of the Code of Corporate Governance. The Board is of the opinion that it is appropriate and in the best interests of the Company for Ms. Sun to hold both positions as it helps to maintain the continuity of the policies and the stability of the operations of the Company.
お知らせ • Mar 13Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2023 Final Results on Mar 28, 2024Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2023 final results on Mar 28, 2024
Reported Earnings • Nov 11Third quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 3Q 2022)Third quarter 2023 results: CN¥0.003 loss per share (improved from CN¥0.004 loss in 3Q 2022). Revenue: CN¥119.3m (up 20% from 3Q 2022). Net loss: CN¥6.04m (loss narrowed 28% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Oct 25Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2023 Results on Nov 09, 2023Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q3, 2023 results on Nov 09, 2023
分析記事 • Sep 12Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Aug 11Second quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 2Q 2022)Second quarter 2023 results: CN¥0.003 loss per share (improved from CN¥0.004 loss in 2Q 2022). Revenue: CN¥99.5m (down 14% from 2Q 2022). Net loss: CN¥5.37m (loss narrowed 25% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Jul 25Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2023 Results on Aug 10, 2023Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2023 results on Aug 10, 2023
分析記事 • Apr 17Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% HidingUnfortunately for some shareholders, the Tianjin TEDA Biomedical Engineering Company Limited ( HKG:8189 ) share price...
分析記事 • Apr 07Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Apr 01Full year 2022 earnings released: CN¥0.015 loss per share (vs CN¥0.022 loss in FY 2021)Full year 2022 results: CN¥0.015 loss per share (improved from CN¥0.022 loss in FY 2021). Revenue: CN¥449.7m (down 5.6% from FY 2021). Net loss: CN¥28.1m (loss narrowed 34% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yongkang Wang was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 15Tianjin TEDA Biomedical Engineering Company Limited Announces Mr. Hao Zhihui Will Retire as an Executive DirectorTianjin TEDA Biomedical Engineering Company Limited announced Mr. Hao Zhihui will retire as an executive director at the EGM with effect from the conclusion of the EGM due to his retirement and will not offer himself for re-election. The number of members of the Board does not meet the requirements of the Company's Articles of Association as it has not yet identified a suitable candidate to succeed as an executive director. The Board will identify a suitable candidate to serve as an executive director as soon as practicable in order to comply with the requirements of the Company's Articles of Association.
Reported Earnings • Nov 13Third quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥0.001 profit in 3Q 2021)Third quarter 2022 results: CN¥0.44 loss per share (down from CN¥0.001 profit in 3Q 2021). Revenue: CN¥99.8m (down 14% from 3Q 2021). Net loss: CN¥8.38m (down CN¥9.39m from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
分析記事 • Nov 01Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Oct 26Tianjin TEDA Biomedical Engineering Company Limited to Report Nine Months, 2022 Results on Nov 10, 2022Tianjin TEDA Biomedical Engineering Company Limited announced that they will report nine months, 2022 results on Nov 10, 2022
お知らせ • Sep 07Tianjin Teda Biomedical Engineering Company Limited Announces Executive ChangesTianjin TEDA Biomedical Engineering Company Limited (the Company) hereby announced that Mr. Qin Wenhua has been appointed as the Joint Chief Executive Officer of the Company and Ms. Sun Li has been re-designated as the Joint Chief Executive Officer of the Company from the Chief Executive Officer of the Company with effect from 6 September 2022. MR. QIN WENHUA Mr. Qin Wenhua (Mr. Qin), aged 56, graduated from Sun Yat-sen University in 1988 with a bachelor's degree in theoretical physics. Mr. Qin has 28 years of experience in business start-up. He has successively led and founded various fast-moving consumer goods companies such as Yunnan Red, Yunnan Shangri La Wine Industry, and Impression Wine Industry, all of which have developed into well-known brands in the industry. Mr. Qin has strategic framework capabilities in product design and positioning, brand marketing, consumer demand mining and service construction. Qin has successively established Jiangsu Weidi Electronic Trading Center Co. Ltd. Shanghai Yunyang Biotechnology Co. Ltd. Shanghai Meika Coffee Co. Ltd., Wisdom Cloud Drink Co. Ltd. Shanghai Weidi Network Technology Co. Ltd. other companies, and has experience in the implementation of and multiple consumer goods DTC projects. Ms. Sun Li (Ms. Sun), aged 49, holds a doctorate degree in Business Administration from the City University of Hong Kong and graduated from Central South University with a bachelor's degree in Technological Economics and with a master 's degree in Administration, respectively. Ms. Sun has engaged in investment banking for 15 years, and was among the first batch of sponsor representatives from the Securities Association of China in 2004. She is a member of Alxa SEE Conservation, an environmental protection charity organization for Chinese entrepreneurs. From May 2013 until now, Sun served as president, director and co-partner of Beijing Yingguxinye Investment Co. Ltd. In September 2014, she was the founding member of Tianjin Teda Wings of the Angel. Investor Club. From May 2015 until now, Sun was appointed as supervisors of Shenzhen Xiangyong Investment Company Limited and Dongguan Lvye Fertilisers Company Limited. From September 2015 until now, Sun, as the beneficial owner of Beijing Tianyuhongtai Technology Co. Ltd. held its 16% shares. From December 2015 until now, she was appointed as a director of Beijing Yingguchuangrong Information Technology Co. Ltd. From August 2015 until now, Ms. Sun was appointed as an executive director and the Chairman. of the Board of the Company. From September 2015 to January 2019 and from 30 December 2019, Ms. Sun concurrently serves Officer of the Company.
Reported Earnings • Aug 10Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CN¥116.0m (down 1.2% from 2Q 2021). Net loss: CN¥7.20m (down CN¥8.18m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 23Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2022 Results on Aug 09, 2022Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2022 results on Aug 09, 2022
お知らせ • Jul 19Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) entered into the Equity Transfer Agreement to acquire Shanghai Weidi Network Technology Company from three shareholders for CNY12.8 million.Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) entered into the Equity Transfer Agreement to acquire Shanghai Weidi Network Technology Company from three shareholders for CNY12.8 million on July 18, 2022. The net asset value of Shanghai Weidi as of 30 June 2022 was RMB13.1 million.
Reported Earnings • May 11First quarter 2022 earnings released: CN¥0.003 loss per share (vs CN¥0 in 1Q 2021)First quarter 2022 results: CN¥0.003 loss per share (down from CN¥0 in 1Q 2021). Revenue: CN¥89.2m (down 28% from 1Q 2021). Net loss: CN¥6.04m (loss widened CN¥5.88m from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yongkang Wang was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 23Tianjin TEDA Biomedical Engineering Company Limited to Report Q1, 2022 Results on May 10, 2022Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q1, 2022 results on May 10, 2022
分析記事 • Apr 21Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Apr 03Full year 2021 earnings releasedFull year 2021 results: Revenue: CN¥476.4m (up 29% from FY 2020). Net loss: CN¥42.3m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Feb 09Tianjin TEDA Biomedical Engineering Company Limited Approves Appointment of Mr. Zhao Zhiyou as the Independent SupervisorTianjin TEDA Biomedical Engineering Company Limited announced that at its special general meeting held on February 8, 2022, shareholders approved the appointment of Mr. Zhao Zhiyou as the independent supervisor of the company for a term commencing from the date of passing this resolution and ending upon the conclusion of the seventh session of the Supervisory Committee.
Reported Earnings • Nov 11Third quarter 2021 earnings released: EPS CN¥0.001 (vs CN¥0.006 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥115.4m (up 34% from 3Q 2020). Net income: CN¥1.01m (up CN¥11.7m from 3Q 2020). Profit margin: 0.9% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
分析記事 • Oct 26Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Aug 10Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥117.4m (up 21% from 2Q 2020). Net income: CN¥975.2k (up 200% from 2Q 2020). Profit margin: 0.8% (up from 0.3% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
分析記事 • Apr 06Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Executive Departure • Apr 02Non-Executive Director has left the companyOn the 26th of March, Li Gai's tenure as Non-Executive Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Li's name. Li is the only executive to leave the company over the last 12 months.
Reported Earnings • Mar 28Full year 2020 earnings released: CN¥0.025 loss per share (vs CN¥0.045 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CN¥369.4m (up 3.0% from FY 2019). Net loss: CN¥48.0m (loss narrowed 43% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 09Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2020 results on Mar 24, 2021
分析記事 • Dec 22Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Oct 28Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2020 Results on Nov 10, 2020Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q3, 2020 results on Nov 10, 2020
お知らせ • Jul 25Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2020 Results on Aug 10, 2020Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2020 results on Aug 10, 2020
